Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention - PubMed (original) (raw)
Review
. 2010 Jun;119(1-3):1-10.
doi: 10.1016/j.schres.2010.02.1071. Epub 2010 Mar 26.
B Nelson, A Thompson, A G Parker, M Kerr, C Macneil, R Fraser, F Hughes, K Crisp, S Harrigan, S J Wood, M Berk, P D McGorry
Affiliations
- PMID: 20347270
- DOI: 10.1016/j.schres.2010.02.1071
Review
Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention
S M Francey et al. Schizophr Res. 2010 Jun.
Abstract
In recent years, early intervention services have attempted to identify people with a first episode of psychosis as early as possible, reducing the duration of untreated psychosis and changing the timing of delivery of interventions. The logic of early intervention is based partly on accessing people in a more treatment responsive stage of illness in which psychosocial damage is less extensive, and partly on remediating a putatively active process of neuroprogression that leads to pathophysiological, symptomatic and structural changes, hence improving symptomatic and functional outcomes. However, as in other areas of health care, earlier identification of new patients may mean that different treatment approaches are indicated. The corollary of early detection is that the sequence and complexion of treatment strategies for first episode psychosis has been revaluated. Examples include the minimal effective dosage of antipsychotic medication and the content of psychosocial interventions. With the substantial reductions of DUP now seen in many early psychosis services, based on clinical staging and stepped care principles, it is even possible that the immediate introduction of antipsychotic medication may not be necessary for all first episode psychosis cases, but that potentially safer interventions, which may be more acceptable to many patients, such as comprehensive psychosocial intervention, may constitute effective treatment at least for a subgroup of patients. In this paper, we review this theoretical background and describe a randomised controlled trial currently underway at the Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne designed to test outcomes for first episode psychosis patients in response to two different treatments: intensive psychosocial intervention plus antipsychotic medication versus intensive psychosocial intervention plus placebo. This is a theoretically and pragmatically novel study in that it will provide evidence as to whether intensive psychosocial intervention alone is sufficient for a subgroup of first episode psychosis patients in a specialised early intervention service, and provide a test of the heuristic clinical staging model. By experimentally manipulating duration of untreated psychosis, the study will also provide a methodologically strong test of the effect of delaying the introduction of antipsychotic medication, as well as helping to disentangle the effects of antipsychotic medications and the putative neurobiological processes associated with brain changes and symptom profiles in the early phase of psychotic disorders. The study has been carefully crafted to satisfy critical ethical demands in this challenging research domain.
Crown Copyright (c) 2010. Published by Elsevier B.V. All rights reserved.
Similar articles
- Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants.
O'Donoghue B, Francey SM, Nelson B, Ratheesh A, Allott K, Graham J, Baldwin L, Alvarez-Jimenez M, Thompson A, Fornito A, Polari A, Berk M, Macneil C, Crisp K, Pantelis C, Yuen HP, Harrigan S, McGorry P. O'Donoghue B, et al. Early Interv Psychiatry. 2019 Aug;13(4):953-960. doi: 10.1111/eip.12716. Epub 2018 Jul 19. Early Interv Psychiatry. 2019. PMID: 30024100 Clinical Trial. - [Specialised first-episode psychosis services: a systematic review of the literature].
Skalli L, Nicole L. Skalli L, et al. Encephale. 2011 May;37 Suppl 1:S66-76. doi: 10.1016/j.encep.2010.08.004. Epub 2010 Oct 12. Encephale. 2011. PMID: 21600336 Review. French. - Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):1-30. doi: 10.1080/j.1440-1614.2005.01516.x. Aust N Z J Psychiatry. 2005. PMID: 15660702 Review. - [Duration of untreated psychosis: A state-of-the-art review and critical analysis].
Souaiby L, Gaillard R, Krebs MO. Souaiby L, et al. Encephale. 2016 Aug;42(4):361-6. doi: 10.1016/j.encep.2015.09.007. Epub 2016 May 6. Encephale. 2016. PMID: 27161262 Review. French.
Cited by
- Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.
Kim B, Lee SH, Yang YK, Park JI, Chung YC. Kim B, et al. Schizophr Res Treatment. 2012;2012:560836. doi: 10.1155/2012/560836. Epub 2012 Aug 14. Schizophr Res Treatment. 2012. PMID: 22966439 Free PMC article. - Psychometric investigation of the French version of the Aberrant Salience Inventory (ASI): differentiating patients with psychosis, patients with other psychiatric diagnoses and non-clinical participants.
Golay P, Laloyaux J, Moga M, Della Libera C, Larøi F, Bonsack C. Golay P, et al. Ann Gen Psychiatry. 2020 Oct 3;19:58. doi: 10.1186/s12991-020-00308-0. eCollection 2020. Ann Gen Psychiatry. 2020. PMID: 33024446 Free PMC article. - Diagnostic and Prognostic Significance of Brief Limited Intermittent Psychotic Symptoms (BLIPS) in Individuals at Ultra High Risk.
Fusar-Poli P, Cappucciati M, De Micheli A, Rutigliano G, Bonoldi I, Tognin S, Ramella-Cravaro V, Castagnini A, McGuire P. Fusar-Poli P, et al. Schizophr Bull. 2017 Jan;43(1):48-56. doi: 10.1093/schbul/sbw151. Schizophr Bull. 2017. PMID: 28053130 Free PMC article. - Diagnostic markers for schizophrenia: do we actually know what we're looking for?
Wood SJ, Yung AR. Wood SJ, et al. World Psychiatry. 2011 Feb;10(1):33-4. doi: 10.1002/j.2051-5545.2011.tb00006.x. World Psychiatry. 2011. PMID: 21379349 Free PMC article. No abstract available. - Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.
Bossie CA, Fu DJ, Sliwa JK, Ma YW, Alphs L. Bossie CA, et al. Ther Adv Psychopharmacol. 2011 Aug;1(4):111-24. doi: 10.1177/2045125311413006. Ther Adv Psychopharmacol. 2011. PMID: 23983935 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical